EUCTR2013-000548-25-ES进行中（未招募）1 期
A Randomized-Controlled Three-arm Phase II Study of Lurbinectedin (PM01183) Alone or In Combination with Gemcitabine and a control arm with Docetaxel as Second-Line Treatment in Unresectable Non-Small Cell Lung Cancer (NSCLC) Patients. - Not applicable
Pharma Mar S.A. Sociedad Unipersonal0 个研究点目标入组 69 人开始时间: 2013年4月9日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 69
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Voluntary written IC of the patient obtained before any study-specific procedure.
- •2) Histologically or cytologically confirmed unresectable NSCLC.
- •3) Patients must have failed one prior line of CT-based therapy for unresectable disease.
- •4) Age between 18 and 75 years, both inclusive.
- •5) Measurable disease as defined by RECIST v1.1.
- •6) Eastern Cooperative Oncology Group (ECOG) performance status (PS) ? 1.
- •7) Adequate hematological, renal, metabolic and hepatic function:
- •a) Hemoglobin ? 9 g/dl (patients may have received prior red blood cell [RBC] transfusion up to 48 hours before
- •treatment start, if clinically indicated), absolute neutrophil count (ANC) ? 2.0 x 109/l, and platelet count ? 100 x 109/l.
- •b) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3.0 x upper limit of normal (ULN) (? 5.0 x ULN if liver metastases are present).
- •c) Total bilirubin ? ULN, or direct bilirubin ? ULN if total bilirubin is > ULN.
- •d) Albumin ? 3.0 g/dl.
- •e) Calculated creatinine clearance (CrCl) ? 30 ml/minute (using Cockcroft and Gault?s formula).
- •f) Creatine phosphokinase (CPK) ? 2.5 x ULN.
- •8) At least three weeks since the last prior therapy, at least four weeks since completion of any prior radiotherapy and recovery to grade ? 1 from any adverse event (AE) derived from previous anticancer treatment, except alopecia, sensory neuropathy, anemia or asthenia (all of which must have recovered to grade ? 2) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE, v.4).
- •9) Pre-menopausal women must have a negative pregnancy test before treatment start, not be breast feeding and agree to use adequate contraception during the whole length of study participation and for at least six weeks after the last study dose of PM01183.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 28
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 12
排除标准
- •1) Concomitant diseases/conditions:
- •a) History (within the last year) or presence of unstable angina, myocardial infarction, symptomatic congestive heart failure or asymptomatic with left ventricular ejection fraction (LVEF) ? 50% (assessed by multiple-gated acquisition scan [MUGA] or equivalent by ultrasound [US]) or clinically significant valvular heart disease.
- •b) Patients with dyspnea at rest or requiring any oxygen support within the last four weeks.
- •c) Known infection by human immunodeficiency virus (HIV), including seropositive patients without AIDs.
- •d) Chronically active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.
- •e) Active uncontrolled infection; patients undergoing active antibiotherapy for an ongoing infection must have finished treatment at least one week before treatment start.
- •f) Pleural or pericardial effusions requiring invasive management procedures.
- •g) Known myopathy of any cause.
- •h) Limitation of the patient?s ability to comply with the treatment or to follow-up the protocol.
- •I) Any other major illness that, in the Investigator?s judgment, will substantially increase the risk associated with the patient?s participation in this study.
- •2) More than one prior line of CT for advanced or unresectable disease.
- •3) Histological features of neuroendocrine or bronchioalveolar differentiation.
- •4) Unknown epidermal growth factor receptor (EGFR) mutation status or previously known EGFR mutated status in patients with adenocarcinoma.
- •5) Prior or concurrent invasive malignant disease, unless in complete remission for more than three years. Exceptions are completely resected or definitively treated squamous cell carcinoma of the cervix or head and neck without lymphatic spread, cutaneous basal cell carcinoma or superficial transitional cell carcinoma of the bladder.
- •6) Significant cancer-related weight loss (?10%) within four weeks prior to treatment start.
- •7) Prior treatment with gemcitabine or docetaxel-containing therapy (one full infusion at least completed).
- •8) Symptomatic, steroid-requiring or progressive CNS involvement. If there is prior or current, known or suspected CNS involvement, clinical stability and lack of radiological progression of lesions should be demonstrated for at least the immediate six weeks before study entry.
- •9) Ongoing symptomatic paraneoplastic syndromes.
研究者
相似试验
进行中（未招募）
1 期
A Clinical Study in Three-arm of Lurbinectedin (PM01183) alone or in combination with Gemcitabine and a control arm with Docetaxel as second-line treatment in Small Cell Lung Cancer (NSCLC) patients.nresectable Non-Small Cell Lung Cancer (NSCLC).MedDRA version: 18.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000548-25-BEPharma Mar S.A. Sociedad Unipersonal120
进行中（未招募）
不适用
A Clinical Study in Three-arm of Lurbinectedin (PM01183) alone or in combination with Gemcitabine and a control arm with Docetaxel as second-line treatment in Small Cell Lung Cancer (NSCLC) patients.nresectable Non-Small Cell Lung Cancer (NSCLC).MedDRA version: 18.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000548-25-FRPharma Mar S.A. Sociedad Unipersonal120
进行中（未招募）
1 期
A Clinical Study in Three-arm of Lurbinectedin (PM01183) alone or in combination with Gemcitabine and a control arm with Docetaxel as second-line treatment in Small Cell Lung Cancer (NSCLC) patients.nresectable Non-Small Cell Lung Cancer (NSCLC).MedDRA version: 16.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2013-000548-25-ITPharma Mar S.A. Sociedad Unipersonal120
进行中（未招募）
1 期
A clinical trial of relacorilant (study drug) with nab-paclitaxel in patients with ovarian, fallopian tube or peritoneal cancerRecurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10016180Term: Fallopian tube cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061344Term: Peritoneal neoplasmSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004186-14-BECorcept Therapeutics Incorporated177
进行中（未招募）
1 期
A clinical trial of relacorilant (study drug) with nab-paclitaxel in patients with ovarian, fallopian tube or peritoneal cancerRecurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal CancerMedDRA version: 20.0 Level: PT Classification code 10033128 Term: Ovarian cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10016180 Term: Fallopian tube cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0 Level: PT Classification code 10061344 Term: Peritoneal neoplasm System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2018-004186-14-ESCorcept Therapeutics Incorporated177